NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis
Withdrawn before enrolling · Phase 1/Phase 2
Conditions studied: Metastatic Melanoma, Melanoma Brain Metastasis
In brief
This research study involves studying a device as a possible treatment for metastatic melanoma in the brain. The purpose of this study is to obtain information on the safety and effectiveness of the study device, NovoTTF-200A, in melanoma participants with brain metastases when it is combined with Pembrolizumab. The name of the study device involved in this study is: \-- NovoTTF-200A The name of the drug used in this study is: \-- Pembrolizumab
Key facts
- Study ID
- NCT04129515
- Run by
- Brown University
- People needed
- 0
- Starts
- 2025-10-30
- Expected to finish
- 2026-01-01
- Last updated by the study team
- 2026-01-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Lifespan Cancer Institute — Providence, Rhode Island, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.